Profile data is unavailable for this security.
About the company
Zydus Lifesciences Limited is an India-based life-sciences company with positions across pharmaceuticals and consumer wellness, supported by a MedTech franchise and a global footprint across United States, India and other international markets. Its pharmaceutical business includes integrated pharmaceutical operations with business encompassing the entire value chain in research, development, production, marketing and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients, human formulations, and animal health and veterinary. Its consumer products business includes development, production, marketing and distribution of differentiated health and wellness products. It provides biologicals manufacturing sites offering contract development and manufacturing organization services to biopharmaceutical companies globally. Its focused therapy areas include cardiology, anti-diabetes, super specialty areas of oncology and nephrology, and others.
- Revenue in INR (TTM)260.89bn
- Net income in INR49.38bn
- Incorporated1995
- Employees27.92k
- LocationZydus Lifesciences LtdZydue Tower, Satellite Cross RoadAHMEDABAD 382481IndiaIND
- Phone+91 7 926868100
- Fax+91 7 926862365
- Websitehttps://www.zyduslife.com/zyduslife/
Mergers & acquisitions
| Acquired company | ZYDUSLIFE:NSI since announced | Transaction value |
|---|---|---|
| Agenus Inc-Manufacturing Facilities(2) | -1.23% | 125.00m |
| Amplitude Surgical SA | 2.61% | 46.79m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laurus Labs Ltd | 67.22bn | 8.43bn | 556.38bn | 6.17k | 66.02 | -- | 42.47 | 8.28 | 15.61 | 15.61 | 124.44 | -- | -- | -- | -- | 10,899,350.00 | -- | 8.88 | -- | 14.31 | 58.67 | 48.18 | 12.52 | 11.88 | -- | 7.10 | -- | 13.79 | 10.18 | 14.42 | 123.18 | 7.02 | 23.60 | -- |
| Glenmark Pharmaceuticals Ltd | 164.68bn | 10.65bn | 575.61bn | 13.48k | 54.07 | -- | 35.62 | 3.50 | 37.72 | 37.72 | 583.32 | -- | -- | -- | -- | 12,219,440.00 | -- | 1.33 | -- | 1.92 | 71.68 | 60.15 | 6.47 | 1.82 | -- | 16.41 | -- | 39.62 | 12.77 | 4.60 | 155.14 | 6.18 | -4.24 | 0.00 |
| Abbott India Ltd | 68.24bn | 15.24bn | 591.26bn | 3.66k | 38.79 | -- | 36.98 | 8.66 | 717.26 | 717.26 | 3,211.47 | -- | -- | -- | -- | 18,650,260.00 | -- | 22.42 | -- | 30.42 | 46.61 | 44.59 | 22.33 | 18.83 | -- | 79.05 | -- | 73.99 | 9.58 | 9.38 | 17.75 | 18.99 | 27.31 | 34.73 |
| Alkem Laboratories Ltd | 142.53bn | 23.71bn | 653.60bn | 18.64k | 27.56 | -- | 23.25 | 4.59 | 198.32 | 198.32 | 1,192.01 | -- | -- | -- | -- | 7,645,478.00 | -- | 12.12 | -- | 17.53 | 64.05 | 60.06 | 17.00 | 14.69 | -- | 18.13 | -- | 28.96 | 2.34 | 9.21 | 20.59 | 13.95 | 13.22 | 12.47 |
| Aurobindo Pharma Ltd | 331.82bn | 34.87bn | 694.29bn | 9.11k | 19.91 | -- | 13.28 | 2.09 | 60.04 | 60.04 | 571.33 | -- | -- | -- | -- | 36,435,560.00 | -- | 8.62 | -- | 12.13 | 59.35 | 53.55 | 10.50 | 12.38 | -- | 14.24 | -- | 7.25 | 9.39 | 6.55 | 9.86 | 4.15 | 11.98 | -- |
| Zydus Lifesciences Ltd | 260.89bn | 49.38bn | 902.49bn | 27.92k | 18.27 | -- | 14.86 | 3.46 | 49.08 | 49.08 | 259.31 | -- | -- | -- | -- | 9,345,309.00 | -- | 10.92 | -- | 16.35 | 73.12 | 63.12 | 18.91 | 16.73 | -- | -- | -- | 17.81 | 18.90 | 10.27 | 17.96 | 30.92 | 13.63 | 25.74 |
| Mankind Pharma Ltd | 138.42bn | 17.75bn | 911.14bn | 27.00k | 51.40 | -- | 34.03 | 6.58 | 42.95 | 43.05 | 334.94 | -- | -- | -- | -- | 5,126,748.00 | -- | 14.93 | -- | 19.39 | 71.39 | 67.59 | 13.00 | 17.70 | -- | 3.64 | -- | 0.00 | 18.98 | 15.79 | 3.90 | 14.03 | 18.41 | -- |
| Lupin Ltd | 261.51bn | 46.45bn | 1.05tn | 19.98k | 21.22 | -- | 17.58 | 4.03 | 108.62 | 108.62 | 603.92 | -- | -- | -- | -- | 13,088,990.00 | -- | 4.53 | -- | 7.16 | 72.62 | 59.70 | 17.86 | 5.95 | -- | 183.80 | -- | 29.13 | 13.48 | 8.11 | 71.41 | -- | 20.11 | 14.87 |
| Cipla Ltd | 283.51bn | 45.46bn | 1.06tn | 30.31k | 23.34 | -- | 19.05 | 3.74 | 56.26 | 56.26 | 350.81 | -- | -- | -- | -- | 9,352,779.00 | -- | 11.89 | -- | 14.49 | 66.53 | 59.55 | 16.03 | 14.74 | -- | 96.40 | -- | 22.40 | 6.88 | 9.97 | 27.93 | 27.80 | 9.14 | 34.08 |
| Dr Reddy's Laboratories Ltd | 346.82bn | 55.68bn | 1.08tn | 26.94k | 19.33 | -- | 14.37 | 3.10 | 66.81 | 66.81 | 416.15 | -- | -- | -- | -- | 12,871,960.00 | -- | 12.15 | -- | 16.94 | 65.76 | 66.18 | 15.92 | 15.81 | -- | 19.79 | -- | 14.69 | 16.54 | 13.26 | 1.38 | 22.84 | 41.26 | 9.86 |
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 01 Aug 2025 | 50.32m | 5.00% |
| PPFAS Asset Management Private Ltd.as of 31 Jan 2026 | 19.57m | 1.95% |
| Kotak Mahindra Asset Management Co. Ltd.as of 30 Jun 2025 | 12.33m | 1.23% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 9.79m | 0.97% |
| ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 8.63m | 0.86% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 5.43m | 0.54% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 4.05m | 0.40% |
| Goldman Sachs Asset Management LPas of 26 Feb 2026 | 2.95m | 0.29% |
| Robeco Institutional Asset Management BVas of 31 Dec 2025 | 2.67m | 0.27% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 2.47m | 0.25% |
